Terms: = Ovarian cancer AND EML4, ENSG00000143924, 27436
5 results:
1. eml4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/eml4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract] [Full Text] [Related]
3. Response to crizotinib in a lung adenocarcinoma patient harboring eml4-ALK translocation with adnexal metastasis: A Case Report.
Wang W; Wu W; Zhang Y
Medicine (Baltimore); 2016 Jul; 95(30):e4221. PubMed ID: 27472693
[TBL] [Abstract] [Full Text] [Related]
4. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.
Micci F; Panagopoulos I; Thorsen J; Davidson B; Tropé CG; Heim S
PLoS Biol; 2014 Feb; 12(2):e1001784. PubMed ID: 24504521
[TBL] [Abstract] [Full Text] [Related]
5. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Yuan Y; Liao YM; Hsueh CT; Mirshahidi HR
J Hematol Oncol; 2011 Apr; 4():16. PubMed ID: 21504625
[TBL] [Abstract] [Full Text] [Related]
